The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the New England CEPAC process, and find out how topics are selected.
New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the New England CEPAC. For more information about past and other upcoming meetings, see the box to the right.
Grappone Conference Center
70 Constitution Avenue
Concord, NH 03301
Opioids are used to treat cases of acute and chronic pain that arise from a variety of causes, ranging from trauma to palliative care for advanced illness. Every year, 100 million people in the United States suffer from pain, 9-12 million of whom have chronic or persistent pain. Although opioid therapy is an important component of pain management for many patients, the addictive and euphoric properties of these drugs make them liable to misuse, abuse, addiction, and diversion.
In an effort to help tackle the public health crisis of opioid dependence, misuse, and addiction that has emerged over the last decade, drug manufacturers have begun to develop abuse-deterrent formulations of opioid medications (ADFs). ICER will review available evidence on the comparative clinical effectiveness and comparative value of ADFs in order to inform decision-making by patients, clinicians and policy-makers, within the context of multiple efforts being undertaken to combat the opioid crisis. ICER’s review will also analyze the potential of ADFs to reduce the burden of prescription opioid abuse by evaluating their benefits and market penetration based on coverage policies and legislation.
Interventions of Interest:
- Hydrocodone (Hysingla® ER, Purdue)
- Hydrocodone (VantrelaTM, Teva)
- Morphine (ArymoTM ER, Egalet)
- Morphine + naltrexone (Embeda®, Pfizer)
- Morphine extended release (MorphabondTM, Inspirion Delivery Technologies)
- Oxycodone (OxyContin® TR, Purdue)
- Oxycodone (XtampzaTM ER, Collegium Pharmaceutical Inc)
- Oxycodone + naloxone extended release (TarginiqTM, Purdue)
- Oxycodone + naltrexone (Troxyca® ER, Pfizer)
Date of Review: July 2017View materials